Peters Christopher A, Stock Richard G, Cesaretti Jamie A, Atencio David P, Peters Sheila, Burri Ryan J, Stone Nelson N, Ostrer Harry, Rosenstein Barry S
Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA.
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):752-9. doi: 10.1016/j.ijrobp.2007.05.023. Epub 2007 Aug 8.
To investigate whether the presence of single nucleotide polymorphisms (SNPs) located within TGFB1 might be predictive for the development of adverse quality-of-life outcomes in prostate cancer patients treated with radiotherapy.
A total of 141 prostate cancer patients treated with radiotherapy were screened for SNPs in TGFB1 using DNA sequencing. Three quality-of-life outcomes were investigated: (1) prospective decline in erectile function, (2) urinary quality of life, and (3) rectal bleeding. Median follow-up was 51.3 months (range, 12-138 months; SD, 24.4 months).
Those patients who possessed either the T/T genotype at position -509, the C/C genotype at position 869 (pro/pro, codon 10) or the G/C genotype at position 915 (arg/pro, codon 25) were significantly associated with the development of a decline in erectile function compared with those who did not have these genotypes: 56% (9 of 16) vs. 24% (11 of 45) (p = 0.02). In addition, patients with the -509 T/T genotype had a significantly increased risk of developing late rectal bleeding compared with those who had either the C/T or C/C genotype at this position: 55% (6 of 11) vs. 26% (34 of 130) (p = 0.05).
Possession of certain TGFB1 genotypes is associated with the development of both erectile dysfunction and late rectal bleeding in patients treated with radiotherapy for prostate cancer. Therefore, identification of patients harboring these genotypes may represent a means to predict which men are most likely to suffer from poor quality-of-life outcomes after radiotherapy for prostate cancer.
研究转化生长因子β1（TGFB1）基因内单核苷酸多态性（SNP）的存在是否可预测接受放疗的前列腺癌患者生活质量不良结局的发生。
对141例接受放疗的前列腺癌患者进行DNA测序，筛查TGFB1基因中的SNP。研究了三项生活质量结局：（1）勃起功能的前瞻性下降；（2）泌尿生活质量；（3）直肠出血。中位随访时间为51.3个月（范围12 - 138个月；标准差24.4个月）。
与不具有这些基因型的患者相比，在-509位点具有T/T基因型、在869位点具有C/C基因型（pro/pro，密码子10）或在915位点具有G/C基因型（arg/pro，密码子25）的患者，勃起功能下降的发生显著相关：56%（16例中的9例）对24%（45例中的11例）（p = 0.02）。此外，与在该位点具有C/T或C/C基因型的患者相比，具有-509 T/T基因型的患者发生晚期直肠出血的风险显著增加：55%（11例中的6例）对26%（130例中的34例）（p = 0.05）。
在接受前列腺癌放疗的患者中，某些TGFB1基因型的存在与勃起功能障碍和晚期直肠出血的发生相关。因此，识别携带这些基因型的患者可能是预测哪些男性在前列腺癌放疗后最有可能出现生活质量不良结局的一种方法。
